More importantly, one recent clinical study involving 54 obese patients with type 2 diabetes revealed that the FDA-approved GLP-1RA exenatide significantly increases the serum level of irisin (Liu et al., 2016). The gene discussed is FNDC5; the disease is type 2 diabetes mellitus.